Takahito Wakamiya
Papers
6
Total Citations
56
H-Index
3
About
Takahito Wakamiya is a leading urologic surgeon and researcher whose work centers on advancing the treatment of prostate cancer, with a particular focus on high-risk disease and the optimization of robot-assisted radical prostatectomy (RARP). His major contributions include pioneering comparative analyses of surgical robotic systems, most notably in his highly cited 2024 study (41 citations) that performed a propensity score-matched comparison of the hinotori™ and da Vinci® systems, demonstrating the safety and efficacy of the newer hinotori™ platform. Dr. Wakamiya has also made significant strides in risk stratification, showing that lymphatic invasion is a critical prognostic factor for biochemical recurrence in high-risk patients, and that local extension findings on MRI can compensate for pathological staging in predicting oncological outcomes. His work extends beyond survival metrics to patient-centered outcomes, as evidenced by his studies comparing health-related quality of life (HRQOL) after RARP versus combined brachytherapy and radiation, and his investigation into the impact of postoperative sexual function on overall HRQOL. Through these integrated clinical and quality-of-life studies, Dr. Wakamiya is helping to define the optimal, individualized treatment pathways for men facing high-risk prostate cancer.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4
- 5
- 6